C4 therapeutics to present preliminary cft1946 monotherapy phase 1 clinical data at the european society for medical oncology (esmo) congress 2024

Abstract released today highlights favorable safety profile and early evidence of monotherapy anti-tumor activity investor webcast to be held friday, september 13, 2024 at 12:00 pm et watertown, mass., sept. 08, 2024 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the abstract sharing clinical data from its ongoing phase 1 clinical trial of cft1946, a novel bidac™ degrader, in mutant braf v600 solid tumors, was released in conjunction with the esmo congress 2024 scheduled for september 13 – 17, 2024 in barcelona, spain.
CCCC Ratings Summary
CCCC Quant Ranking